论文部分内容阅读
新英格兰医学中心等单位的研究人员进行了一项前瞻性随机试验检测经静脉内注入巨细胞病毒(CMV)免疫球蛋白是否能预防肾移植受者的原发性CMV疾病。59名CMV血清阴性病人被分为接受静脉内CMV免疫球蛋白组和非治疗组,这些病人曾接受了有CMV抗体供者的肾脏。在移植后头4个月内分多次投给免疫球蛋白。通过病毒学测定证实CMV相关的综合征的发病率:对照组为60％,CMV免疫球蛋白的治疗组则为21％(P<0.01)。治疗组仅4％的患者有白细胞减少(严重CMV病的表现)而对照组有37％(P<0.O1)。
Researchers from the New England Medical Center conducted a prospective randomized trial to examine whether intravenous injection of cytomegalovirus (CMV) immunoglobulin can prevent primary CMV disease in kidney transplant recipients. Fifty-nine CMV seronegative patients were divided into intravenous CMV immunoglobulin groups and untreated patients who had received the kidney with CMV antibody donor. In the first four months after transplantation points for multiple immunoglobulin. The incidence of CMV-related syndromes was confirmed by virological assays: 60% in the control group and 21% in the CMV immunoglobulin treated group (P <0.01). Only 4% of patients in the treatment group had leukopenia (a manifestation of severe CMV disease) compared with 37% in the control group (P <0.O1).